SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) — Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired QuidelOrtho Corporation f/k/a Quidel (NASDAQ:) Corporation (NASDAQ: QDEL) common stock between February 18, 2022 and April 1, 2024. QuidelOrtho provides tests for the detection and diagnosis of various respiratory diseases and other medical conditions.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
The Allegations: Robbins LLP is Investigating the Allegations that QuidelOrtho Corporaiton (QDEL) Misled Investors Regarding Demand for its Product
According to the complaint, defendants assured investors that QuidelOrtho was well positioned to maintain a stable high margin revenue stream from its respiratory business. Among other strategies, the Company aimed to launch its next flagship product, a new test called the Savanna Respiratory Viral Panel-4 (the Savanna RVP4 Test, which tests for COVID-19 and other respiratory conditions) by utilizing its commercial distribution network.
However, plaintiff alleges that, during the class period, defendants failed to disclose that: (a) QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers; (b) excess inventories of COVID-19 tests existed throughout the supply chain; and (c) as a result, QuidelOrtho’s distributors and pharmacy chain customers were poised to significantly reduce their COVID-19 test orders. When the truth was revealed, the price of QuidelOrtho stock dropped $21.50, or more than 32%, to close at $45.27 on February 14, 2024.
remove ads
.
Plaintiff further alleges that undisclosed problems created a heightened risk that the Savanna RVP4 Test would experience a delayed commercial launch in the United States. On April 2, 2024, after QuidelOrtho announced it had withdrawn its FDA 510(k) submission for approval to sell Savanna PVPR Test in the U.S., the Company’s stock dropped $4.85, or more than 10%, to close at $42.15 on April 2, 2024.
What Now: You may be eligible to participate in the class action against QuidelOrtho Corporation. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by June 11, 2024. A lead plaintiff is a representative…
Click Here to Read the Full Original Article at All News…
